SENSUS HEALTHCARE DL-,01 Aktie

At Sensus Healthcare’s annual meeting, Eric Sachetta and Michael J. Sardano were re-elected as Class II directors for three-year terms. Shareholders also voted, in a non-binding advisory vote, to approve executive compensation for 2025 and ratified Carr, Riggs & Ingram as the independent auditor for fiscal year 2026. Sensus reported weak Q1 results with EPS of -$0.16 and revenue of $3.4 million, while the stock is trading near its 52-week low. » Mere på de.investing.com

Sensus Healthcare reported Q1 2026 EPS of -$0.16 and revenue of $3.4 million, both below analyst expectations. Revenue fell 59% year over year, weighed down by missed sales to its largest customer and a shift to new business models. Adjusted revenue growth on a comparable basis was +26%. Management sees potential in new specific CPT codes and the Sensus Link software platform to improve reimbursement and drive future revenue growth. » Mere på de.investing.com

Sensus Healthcare dismissed Berkowitz Pollack Brant Advisors + CPAs (BPB) and appointed Carr, Riggs & Ingram (CRI) as its new independent auditor after CRI acquired certain assets of BPB’s capital markets business (effective Jan. 1, 2026). BPB’s audit report for the fiscal year ended Dec. 31, 2024, contained no disclaimers, modifications or disagreements with Sensus. The company also reported that a previously disclosed material IT-related control weakness had been remediated as of Dec. 31, 2024. In addition, Sensus reported revenue that exceeded expectations in the third quarter of 2025 and several board and management personnel changes, including the appointment of Larry Biscotti to the board of directors and the promotion of Michael Sardano to chief commercial officer. » Mere på de.investing.com

Sensus Healthcare has appointed Eric Sachetta to its board of directors; he replaces the late longtime member Bill McCall. Sachetta comes from Sachetta, LLC and brings experience in financial advisory, leadership and client service, as well as several professional qualifications. The micro‑cap company (about $69m) has recently seen a share-price rise but is struggling with profitability; for Q3/2025 Sensus beat revenue and earnings forecasts (revenue $6.9m, loss per share $0.06). » Mere på de.investing.com

Sensus Healthcare reported Q3 2025 revenue of $6.9 million, topping the forecast of $6.25 million. Earnings per share were -$0.06 versus an expected -$0.08, and the net loss was $0.9 million. Gross margin fell to 39.1%, while the cash position rose to $24.5 million. Management points to new reimbursement codes and international expansion (focus on Japan) as growth drivers; the stock increased 5.15% in after-hours trading. » Mere på de.investing.com